A drug pocket at the lipid bilayer–potassium channel interface
Author(s) -
Nina E. Ottosson,
Malin Silverå Ejneby,
Xiongyu Wu,
Samira Yazdi,
Peter Konradsson,
Erik Lindahl,
Fredrik Elinder
Publication year - 2017
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.1701099
Subject(s) - lipid bilayer , bilayer , potassium channel , interface (matter) , biophysics , channel (broadcasting) , chemistry , voltage gated potassium channel , nanotechnology , molecule , materials science , membrane , biochemistry , computer science , biology , computer network , organic chemistry , gibbs isotherm
Many pharmaceutical drugs against neurological and cardiovascular disorders exert their therapeutic effects by binding to specific sites on voltage-gated ion channels of neurons or cardiomyocytes. To date, all molecules targeting known ion channel sites bind to protein pockets that are mainly surrounded by water. We describe a lipid-protein drug-binding pocket of a potassium channel. We synthesized and electrophysiologically tested 125 derivatives, analogs, and related compounds to dehydroabietic acid. Functional data in combination with docking and molecular dynamics simulations mapped a binding site for small-molecule compounds at the interface between the lipid bilayer and the transmembrane segments S3 and S4 of the voltage-sensor domain. This fundamentally new binding site for small-molecule compounds paves the way for the design of new types of drugs against diseases caused by altered excitability.
Funding Agencies|Swedish Research Council; Swedish Brain Foundation; Swedish Heart-Lung Foundation; Swedish National Infrastructure for Computing
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom